Trial Site Detail
Drug: |
Nilotinib and Imatinib |
|||
|---|---|---|---|---|
Trial: |
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Terminated |
|||
Fox Chase Cancer Center333 Cottman Ave |
Principal Investigator: |
Margeret von Mehren, M.D. |
|---|---|
Contact: |
Monica Davey, RN 1-888-FOX-CHASE monica.davey@fccc.edu |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Fox Chase Cancer Center Website: |
https://www.protonet.fccc.edu/fccc/pims/ |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.